Standout Papers

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Pri... 2016 2026 2019 2022 301
  1. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment (2016)
    Roy Fleischmann, Michael Schiff et al. Arthritis & Rheumatology
  2. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II) (2023)
    Michelle Petri, Ian N Bruce et al. The Lancet
  3. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) (2023)
    Eric F. Morand, Edward M Vital et al. The Lancet

Immediate Impact

62 standout
Sub-graph 1 of 21

Citing Papers

Atopic dermatitis
2025 Standout
Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders
2024 Standout
1 intermediate paper

Works of Christina Dickson being referenced

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)
2023 Standout
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis
2020
and 1 more

Author Peers

Author Last Decade Papers Cites
Christina Dickson 658 168 269 225 13 876
Joel C. Silverfield 537 124 247 145 13 976
Charles Ludivico 729 226 349 165 13 986
Ying Zhang 702 155 350 220 15 1.0k
Christine E. Codding 601 130 266 174 9 1.1k
Antonio Sánchez 666 152 333 101 19 975
Jeffrey Neal 596 135 312 89 9 840
Agnes L. Maier 624 214 356 95 22 1.1k
Z Domljan 652 104 299 156 18 1.1k
Kahaku Emoto 569 187 284 176 9 794
Nasser Khan 682 180 334 246 27 953

All Works

Loading papers...

Rankless by CCL
2026